CG Oncology prices larger-than-expected $380M IPO in hopeful sign for biotech

Cancer drug developer CG Oncology has raised $380 million in an initial public offering than was larger than it expected, a positive sign for a sector that’s struggled to generate demand from Wall Street investors recently.